Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
about
Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathwayProfile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisType I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesNew Oral Therapies for Psoriasis: A Comprehensive ReviewImpact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightPharmacologic inhibition of JAK-STAT signaling promotes hair growthSafety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areataOral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.Current status and future prospects for biologic treatments of psoriasis.JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin DiseasesTreatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsPregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesOral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.Secukinumab (AIN457) for the treatment of psoriasis.Novel systemic therapies for the treatment of psoriasis.Secukinumab (AIN-457) for the treatment of Psoriasis.Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.Combination of MALDI-MSI and cassette dosing for evaluation of drug distribution in human skin explant.Emerging drugs for psoriatic arthritis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.JAK inhibition in inflammatory bowel disease.Jak3 deficiency blocks innate lymphoid cell development.The Inflammatory Response in Psoriasis: a Comprehensive Review.Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.A Review of Psoriasis, Therapies, and Suicide.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Tofacitinib for the treatment of psoriasis.Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.
P2860
Q26746697-E91CA1B8-EF5F-48DC-B99D-9BF051150E33Q26765028-E05A48B2-6407-4D39-9882-51148F12767DQ26775111-9C8C24FF-89A5-4FAF-997E-F586CB29544CQ28071475-CCEBA157-C0C5-4A0B-A4D8-0A09AF4BF6F0Q33625546-6FB0C7AC-5787-46F0-941D-BFD41307AA33Q33729774-7434E4A8-92EB-40C8-8E4D-BF803CB32566Q34502857-0E81DEE9-7092-4F03-92E6-1B9D018CF3DFQ34541893-62CD9BA4-D8F4-4023-BFCE-C705A74045D8Q34541899-7692539A-80F4-45BE-AEB8-99E0EAFA5735Q36057909-00928794-C4B6-400B-82CE-8EEBC891F64AQ36155239-1D2C09C7-5274-43DC-AC1C-6BF2DF897480Q36157003-78EF9B58-B24F-4FFF-B51D-ED8415F5ECBAQ36190962-B76738B9-9AE3-414D-B43B-F033A464BACFQ37067150-85752A9F-4362-4691-ABEC-092023ACBEBEQ37098500-881F999C-C711-485D-B059-0DB237DBB6FAQ37148745-E84B6709-5E7D-40AE-9954-53968431477CQ37345488-83F80601-7C24-4122-ABD2-03B2B80F7AE3Q37362082-94996AFA-B886-45AE-B4DD-CE7A5947073BQ37412781-354F8DA1-35F8-40CC-9572-81F7A6D73EBDQ37484842-EADA4BBD-01AA-4E8D-A1E2-9E6BC9D6A95FQ37631750-FA7657C8-24D9-4723-AD95-4B633427D0BFQ38597111-A8FE06CB-B4F9-4CD8-832B-9BF7DD708AA9Q38628193-9D641B48-7988-47BB-9E22-2821C9045233Q38662868-4DCF78CE-257C-44AE-9C00-089F76AE6456Q38668352-D5F0329B-549B-4A95-A62C-7292072AF69EQ38688777-C27D80DD-8E66-484E-89FF-B8388B5231BEQ38710642-C28BE946-D875-4584-8C7F-15FE861547E2Q38751230-FE7A6BF2-49A2-426A-B779-ABF34D8B9ECBQ38753877-840C1540-EF66-427F-A744-85A6CE8B51ABQ38761142-72F9368E-221D-4ABF-94FA-664E0E9DC5DFQ38780967-828AE6AC-6A88-4CE6-A909-6A68894F0910Q38792930-126C65C9-1805-4734-902B-0407D1AF2738Q38799023-CD404A44-1AED-4806-9443-AFF0038607A4Q38831055-60D57AA2-D25E-4F26-9992-643E6DA81CE1Q38840271-0202D95C-E0B8-4FBF-BBE2-F8B11785492BQ38856226-17348D83-5C98-435C-86AE-53F7E8EB3516Q38856883-A1E37A47-EDC2-4F6E-8322-3CE866F1B42FQ38862695-34E1A9C1-1F63-4FFF-AA43-9DCF3250712EQ38879975-34BB7D43-ADB0-4F5F-8EFD-415E7C256E7AQ38895147-723DC564-87F8-4C18-81AA-8CC24C08337B
P2860
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@ast
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@en
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@nl
type
label
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@ast
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@en
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@nl
prefLabel
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@ast
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@en
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@nl
P2093
P1433
P1476
Tofacitinib versus etanercept ...... domised non-inferiority trial.
@en
P2093
Fernando Valenzuela
Hernan Valdez
Huaming Tan
James Proulx
Jocelyne Papacharalambous
Joo-Heung Lee
Margaret Tawadrous
OPT Compare Investigators
Pankaj Gupta
Peter C M van de Kerkhof
P304
P356
10.1016/S0140-6736(14)62113-9
P407
P577
2015-06-04T00:00:00Z